Bryan F. Cox

3.6k total citations
85 papers, 1.8k citations indexed

About

Bryan F. Cox is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Physiology. According to data from OpenAlex, Bryan F. Cox has authored 85 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Molecular Biology, 26 papers in Cardiology and Cardiovascular Medicine and 16 papers in Physiology. Recurrent topics in Bryan F. Cox's work include Cardiac electrophysiology and arrhythmias (20 papers), Ion channel regulation and function (15 papers) and Cardiac Ischemia and Reperfusion (11 papers). Bryan F. Cox is often cited by papers focused on Cardiac electrophysiology and arrhythmias (20 papers), Ion channel regulation and function (15 papers) and Cardiac Ischemia and Reperfusion (11 papers). Bryan F. Cox collaborates with scholars based in United States, United Kingdom and Indonesia. Bryan F. Cox's co-authors include Gary A. Gintant, Ruth L. Martin, Jeff S. McDermott, Zhi Su, Craig D. Wegner, James T. Limberis, James S. Polakowski, Jason A. Segreti, Glenn A. Reinhart and Gilbert Diaz and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and NeuroImage.

In The Last Decade

Bryan F. Cox

83 papers receiving 1.8k citations

Peers

Countries citing papers authored by Bryan F. Cox

Since Specialization

Citations

This map shows the geographic impact of Bryan F. Cox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan F. Cox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan F. Cox more than expected).

Fields of papers citing papers by Bryan F. Cox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan F. Cox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan F. Cox. The network helps show where Bryan F. Cox may publish in the future.

Co-authorship network of co-authors of Bryan F. Cox

This figure shows the co-authorship network connecting the top 25 collaborators of Bryan F. Cox. A scholar is included among the top collaborators of Bryan F. Cox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryan F. Cox. Bryan F. Cox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pressure enabled drug delivery (PEDD) of nelitolimod increased therapeutic delivery, reduced immunosuppression, and improved efficacy in porcine and murine liver tumor models 2025 ·Frontiers in Oncology ·(unknown), Yujia Liu, David Jaroch, Thomas G. Hullinger, Bryan F. Cox, Steven C. Katz, (unknown), (unknown), (unknown), Chandra C. Ghosh, Prajna Guha	0
2	PERIO-02: Phase 1b pressure enabled regional immuno-oncology trial of nelitolimod (SD-101), a class C TLR9 agonist, delivered via hepatic artery infusion +/- checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma. 2024 ·Journal of Clinical Oncology ·Sunyoung S. Lee, Khaldoun Almhanna, (unknown), Shubham Pant, J. Kuban, Aaron Maxwell, (unknown), (unknown), (unknown), Bryan F. Cox, Richard D. Carvajal, Ruth A. White, Joshua Weintraub, (unknown), James Hart, Robert Knight, Steven C. Katz, Milind Javle	3
3	Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases 2024 ·Journal for ImmunoTherapy of Cancer ·Chandra C. Ghosh, (unknown), Yujia Liu, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Bryan F. Cox, Evgeny Yakirevich, Diana O. Treaba, Timothy D. Murtha, Prajna Guha, Steven C. Katz, Diwakar Davar	6
4	Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model 2024 ·Journal of Vascular and Interventional Radiology ·David Jaroch, Yujia Liu, (unknown), Steven C. Katz, Bryan F. Cox, Thomas G. Hullinger	4
5	Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model. 2023 ·Journal of Clinical Oncology ·Benedict R. Capacio, (unknown), Diego Vicente, Yujia Liu, (unknown), Bryan F. Cox, David Jaroch, Steven C. Katz, Rebekah R. White	0
6	Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition 2022 ·Cancer Gene Therapy ·Chandra C. Ghosh, (unknown), (unknown), (unknown), Deborah Greer, (unknown), Prajna Guha, Bryan F. Cox, Steven C. Katz	8
7	Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model 2020 ·Surgery ·Jayanth S. Shankara Narayanan, Diego Vicente, Partha Ray, (unknown), (unknown), Matthew Carr, (unknown), Bryan F. Cox, David Jaroch, Steven C. Katz, Rebekah R. White	4
8	Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers 2012 ·Life Sciences ·Xiaoqin Liu, James T. Limberis, Zhi Su, Kathryn Houseman, Gilbert Diaz, Gary A. Gintant, Bryan F. Cox, Ruth L. Martin	9
9	Computer-assisted imaging algorithms facilitate histomorphometric quantification of kidney damage in rodent renal failure models 2012 ·Journal of Pathology Informatics ·(unknown), Gerard D. Gagné, Sherry J. Morgan, (unknown), Bruce E. LeRoy, Eric A.G. Blomme, Bryan F. Cox, Eugene W. Shek	28
10	Capsaicin-induced inhibition of platelet aggregation is not mediated by transient receptor potential vanilloid type 1 2011 ·Blood Coagulation & Fibrinolysis ·Scott W. Mittelstadt, Richard Alan Nelson, Jerome F. Daanen, Andrew J. King, Michael E. Kort, Philip R. Kym, Nathan L. Lubbers, Bryan F. Cox, James J. Lynch	22
11	Magnetic Resonance Imaging Detection and Time Course of Cerebral Microhemorrhages during Passive Immunotherapy in Living Amyloid Precursor Protein Transgenic Mice 2010 ·Journal of Pharmacology and Experimental Therapeutics ·Feng Luo, Nathan R. Rustay, Terese Seifert, (unknown), Vincent P. Hradil, Heinz Hillen, Ulrich Ebert, Jean M. Severin, Bryan F. Cox, Daniel A. Llano, Mark L. Day, Gerard B. Fox	22
12	Tumour‐selective antivascular effects of the novel anti‐mitotic compound A‐318315: Anin vivorat regional haemodynamic study 2010 ·Clinical and Experimental Pharmacology and Physiology ·Jason A. Segreti, (unknown), Kennan C. Marsh, Joy Bauch, Yan Lan, C. Thomas Lin, Saul H. Rosenberg, Hing L. Sham, Glenn A. Reinhart, Bryan F. Cox, James S. Polakowski	3
13	Diacylglycerol Acyltransferase 1 Inhibition Lowers Serum Triglycerides in the Zucker Fatty Rat and the Hyperlipidemic Hamster 2009 ·Journal of Pharmacology and Experimental Therapeutics ·Andrew King, Jason A. Segreti, (unknown), Andrew J. Souers, Philip R. Kym, Regina M. Reilly, Gang Zhao, Scott W. Mittelstadt, Bryan F. Cox	40
14	Hydroxypropyl β-Cyclodextrins: A Misleading Vehicle for the In Vitro hERG Current Assay 2007 ·Journal of Cardiovascular Pharmacology ·(unknown), (unknown), (unknown), Michelle A. Long, James T. Limberis, Ruth L. Martin, Bryan F. Cox, Gary A. Gintant, Zhi Su	10
15	ALTERING EXTRACELLULAR POTASSIUM CONCENTRATION DOES NOT MODULATE DRUG BLOCK OF HUMAN ETHER‐A‐GO‐GO‐RELATED GENE (hERG) CHANNELS 2006 ·Clinical and Experimental Pharmacology and Physiology ·James T. Limberis, Zhi Su, Bryan F. Cox, Gary A. Gintant, Ruth L. Martin	10
16	Pharmacological Characterization of the Novel Dihydropyridine Potassium Channel Opener, (9R)-9-(3-Iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e]pyridine-1,8(4H,7H)-dione (A-325100), and the Regulation of Cardiovascular Function in Conscious and Anesthetized Beagle Dogs 2005 ·Journal of Cardiovascular Pharmacology ·Ryan M. Fryer, (unknown), Lee C. Preusser, Michael E. Brune, William A. Carroll, Steven A. Buckner, Char‐Chang Shieh, (unknown), Kennan C. Marsh, Murali Gopalakrishnan, Bryan F. Cox, Glenn A. Reinhart	6
17	Cardiovascular Pharmacology of the Adenosine A1/A2-Receptor Agonist AMP 579: Coronary Hemodynamic and Cardioprotective Effects in the Canine Myocardium 1999 ·Journal of Cardiovascular Pharmacology ·Matthew J. McVey, Glenn J. Smits, Bryan F. Cox, Jan M. Kitzen, Kenneth L. Clark, Mark H. Perrone	32
18	Ischaemia/reperfusion selectively attenuates coronary vasodilatation to an adenosine A₂‐ but not to an A₁‐agonist in the dog 1994 ·British Journal of Pharmacology ·Bryan F. Cox, (unknown), Mark H. Perrone, Linda Merkel	10
19	Selective Adenosine-2 Agonist Produces Both Direct and Reflex Tachycardia in Normotensive Rats 1992 ·Journal of Cardiovascular Pharmacology ·Rodney W. Lappe, Jeffrey H. Sheldon, Bryan F. Cox	14
20	Tonic Control of Arterial Pressure and Regional Hemodynamics by Supra-Medullary Sites 1991 ·Clinical and Experimental Hypertension Part A Theory and Practice ·Bryan F. Cox, Michael J. Brody	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact